|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Friedmann AM and Weinstein HJ: The role of
prognostic features in the treatment of childhood acute
lymphoblastic leukemia. Oncologist. 5:321–328. 2000.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hunger SP and Mullighan CG: Acute
lymphoblastic leukemia in children. N Engl J Med. 373:1541–1552.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mohiuddin IS, Wei SJ and Kang MH: Role of
OCT4 in cancer stem-like cells and chemotherapy resistance. Biochim
Biophys Acta Mol Basis Dis. 1866(165432)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Terwilliger T and Abdul-Hay M: Acute
lymphoblastic leukemia: A comprehensive review and 2017 update.
Blood Cancer J. 7(e577)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Di J, Duiveman-de Boer T, Zusterzeel PL,
Figdor CG, Massuger LF and Torensma R: The stem cell markers Oct4A,
Nanog and c-Myc are expressed in ascites cells and tumor tissue of
ovarian cancer patients. Cell Oncol (Dordr). 36:363–374.
2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jerabek S, Merino F, Schöler HR and
Cojocaru V: OCT4: dynamic DNA binding pioneers stem cell
pluripotency. Biochim Biophys Acta. 1839:138–154. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Shen L, Qin K, Wang D, Zhang Y, Bai N,
Yang S, Luo Y, Xiang R and Tan X: Overexpression of Oct4 suppresses
the metastatic potential of breast cancer cells via Rnd1
downregulation. Biochim Biophys Acta. 1842:2087–2095.
2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Li SW, Wu XL, Dong CL, Xie XY, Wu JF and
Zhang X: The differential expression of OCT4 isoforms in cervical
carcinoma. PLoS One. 10(e0118033)2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Panagopoulos I, Möller E, Collin A and
Mertens F: The POU5F1P1 pseudogene encodes a putative protein
similar to POU5F1 isoform 1. Oncol Rep. 20:1029–1033.
2008.PubMed/NCBI
|
|
11
|
Mirzaei MR, Kazemi Arababadi M, Asadi MH
and Mowla SJ: Altered expression of high molecular weight heat
shock proteins after OCT4B1 suppression in human tumor cell lines.
Cell J. 17:608–616. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Yasuda H, Tanaka K, Okita Y, Araki T,
Saigusa S, Toiyama Y, Yokoe T, Yoshiyama S, Kawamoto A, Inoue Y, et
al: CD133, OCT4, and NANOG in ulcerative colitis-associated
colorectal cancer. Oncol Lett. 2:1065–1071. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Guzel E, Karatas OF, Duz MB, Solak M,
Ittmann M and Ozen M: Differential expression of stem cell markers
and ABCG2 in recurrent prostate cancer. Prostate. 74:1498–1505.
2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lee SH, Koo BS, Kim JM, Huang S, Rho YS,
Bae WJ, Kang HJ, Kim YS, Moon JH and Lim YC: Wnt/β-catenin
signalling maintains self-renewal and tumourigenicity of head and
neck squamous cell carcinoma stem-like cells by activating Oct4. J
Pathol. 234:99–107. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kong D, Su G, Zha L, Zhang H, Xiang J, Xu
W, Tang Y and Wang Z: Coexpression of HMGA2 and Oct4 predicts an
unfavorable prognosis in human gastric cancer. Med Oncol.
31(130)2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Picot T, Aanei CM, Fayard A,
Flandrin-Gresta P, Tondeur S, Gouttenoire M, Tavernier-Tardy E,
Wattel E, Guyotat D and Campos L: Expression of embryonic stem cell
markers in acute myeloid leukemia. Tumour Biol.
39(1010428317716629)2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Picot T, Kesr S, Wu Y, Aanei CM,
Flandrin-Gresta P, Tondeur S, Tavernier E, Wattel E, Guyotat D and
Campos L: Potential role of OCT4 in leukemogenesis. Stem Cells Dev.
26:1637–1647. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yin JY, Tang Q, Zhai LL, Zhou LY, Qian J,
Lin J, Wen XM, Zhou JD, Zhang YY, Zhu XW and Deng ZQ: High
expression of OCT4 is frequent and may cause undesirable treatment
outcomes in patients with acute myeloid leukemia. Tumour Biol.
36:9711–9716. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Xiang Y and Zhou X: Octamer-binding
transcription factor 4 correlates with complex karyotype, FLT3-ITD
mutation and poorer risk stratification, and predicts unfavourable
prognosis in patients with acute myeloid leukaemia. Hematology.
23:721–728. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Meier P, Antonov J, Zbinden R, Kuhn A,
Gloekler S, Delorenzi M, Jaggi R and Seiller C: Non-invasive
gene-expression-based detection of well-developed collateral
function in individuals with and without coronary artery disease.
Heart. 95:900–908. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Holleman A, Cheok MH, den Boer ML, Yang W,
Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, et al:
Gene-expression patterns in drug-resistant acute lymphoblastic
leukemia cells and response to treatment. N Engl J Med.
351:533–542. 2004.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kaizer EC, Glaser CL, Chaussabel D,
Bancereau J, Pascual V and White PC: Gene expression in peripheral
blood mononuclear cells from children with diabetes. J Clin
Endocrinol Metab. 92:3705–3711. 2007.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wei G, Tworney D, Lamb J, Schlis K,
Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Golub TR
and Armstrong SA: Gene expression-based chemical genomics
identifies rapamycin as a modulator of MCL1 and glucocorticoid
resistance. Cancer Cell. 10:331–342. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gómez-Gómez Y, Organista-Nava J,
Saavedra-Herrera MV, Rivera-Ramírez AB, Terán-Porcayo MA, Del
Carmen Alarcón-Romero L, Illades-Aguiar B and Leyva-Vázquez MA:
Survival and risk of relapse of acute lymphoblastic leukemia in a
Mexican population is affected by dihydrofolate reductase gene
polymorphisms. Exp Ther Med. 3:665–672. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Buchmann S, Schrappe M, Baruchel A, Biondi
A, Borowitz M, Campbell M, Cario G, Cazzaniga G, Escherich G and
Harrison CJ: , et al: Remission, treatment failure, and
relapse in pediatric ALL: An international consensus of the
Ponte-di-Legno Consortium. Blood. 139:1785–1793. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Asadi MH, Mowla SJ, Fathi F, Aleyasin A,
Asadzadeh J and Atlasi Y: OCT4B1, a novel spliced variant of OCT4,
is highly expressed in gastric cancer and acts as an antiapoptotic
factor. Int J Cancer. 128:2645–2652. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nolan T, Hands RE and Bustin SA:
Quantification of mRNA using real-time RT-PCR. Nat Protoc.
1:1559–1582. 2006.PubMed/NCBI View Article : Google Scholar
|
|
28
|
DiGiusto D, Chen S, Combs J, Webb S,
Namikawa R, Tsukamoto A, Chen BP and Galy AH: Human fetal bone
marrow early progenitors for T, B, and myeloid cells are found
exclusively in the population expressing high levels of CD34.
Blood. 84:421–432. 1994.PubMed/NCBI
|
|
29
|
Jiang Z, Wu D, Lin S and Li P: CD34 and
CD38 are prognostic biomarkers for acute B lymphoblastic leukemia.
Biomark Res. 4(23)2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
O'Reilly E, Zeinabad HA and Szegezdi E:
Hematopoietic versus leukemic stem cell quiescence: Challenges and
therapeutic opportunities. Blood Rev. 50(100850)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Lapidot T, Sirard C, Vormoor J, Murdoch B,
Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and
Dick JE: A cell initiating human acute myeloid leukaemia after
transplantation into SCID mice. Nature. 367:645–648.
1994.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang X and Dai J: Concise review: Isoforms
of OCT4 contribute to the confusing diversity in stem cell biology.
Stem Cells. 28:885–893. 2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lee J, Kim HK, Rho JY, Han YM and Kim J:
The human OCT-4 isoforms differ in their ability to confer
self-renewal. J Biol Chem. 281:33554–33565. 2006.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Atlasi Y, Mowla SJ, Ziaee SA and Bahrami
AR: OCT-4, an embryonic stem cell marker, is highly expressed in
bladder cancer. Int J Cancer. 120:1598–1602. 2007.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Atlasi Y, Mowla SJ, Ziaee SA, Gokhale PJ
and Andrews PW: OCT4 spliced variants are differentially expressed
in human pluripotent and nonpluripotent cells. Stem Cells.
26:3068–3074. 2008.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Clemente-Periván SI, Gómez-Gómez Y,
Leyva-Vázquez MA, Lagunas-Martínez A, Organista-Nava J and
Illades-Aguiar B: Role of Oct3/4 in cervical cancer tumorigenesis.
Front Oncol. 10(247)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wang YD, Cai N, Wu XL, Cao HZ, Xie LL and
Zheng PS: OCT4 promotes tumorigenesis and inhibits apoptosis of
cervical cancer cells by miR-125b/BAK1 pathway. Cell Death Dis.
4(e760)2013.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Gómez-Gómez Y, Organista-Nava J,
Clemente-Periván SI, Lagunas-Martínez A, Salmerón-Bárcenas EG,
Villanueva-Morales D, Ayala-Reyna DY, Del Carmen Alarcón-Romero L,
Ortiz-Ortiz J, Jiménez-López MA, et al: The expression of Oct3/4A
mRNA and not its isoforms is upregulated by the HPV16 E7
oncoprotein. Mol Biol Rep. 50:981–991. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhao Q, Ren H, Feng S, Chi Y, He Y, Yang
D, Ma F, Li J, Lu S, Chen F, et al: Aberrant expression and
significance of OCT-4A transcription factor in leukemia cells.
Blood Cells Mol Dis. 54:90–96. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Lin SC, Chung CH, Chung CH, Kuo MH, Hsieh
CH, Chiu YF, Shieh YS, Chou YT and Wu CW: OCT4B mediates
hypoxia-induced cancer dissemination. Oncogene. 38:1093–1105.
2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Farashahi Yazd E, Rafiee MR, Soleimani M,
Tavallaei M, Salmani MK and Mowla SJ: OCT4B1, a novel spliced
variant of OCT4, generates a stable truncated protein with a
potential role in stress response. Cancer Lett. 309:170–175.
2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Aref S, Khaled O, Menshawy NE, Azmy E,
Aref M, Salama O and Khaled N: Significance of OCT3/4 and SOX2
antigens expression by leukemic blast cells in adult acute
leukemia. J Egypt Natl Canc Inst. 36(5)2024.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lu CS, Shieh GS, Wang CT, Su BH, Su YC,
Chen YC, Su WC, Wu P, Yang WH, Shiau AL and Wu CL:
Chemotherapeutics-induced Oct4 expression contributes to drug
resistance and tumor recurrence in bladder cancer. Oncotarget.
8:30844–30858. 2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Gwak JM, Kim M, Kim HJ, Jang MH and Park
SY: Expression of embryonal stem cell transcription factors in
breast cancer: Oct4 as an indicator for poor clinical outcome and
tamoxifen resistance. Oncotarget. 8:36305–36318. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Gatti M, Solari A, Pattarozzi A,
Campanella C, Thellung S, Maniscalco L, De Maria R, Würth R,
Corsaro A, Bajetto A, et al: In vitro and in vivo characterization
of stem-like cells from canine osteosarcoma and assessment of drug
sensitivity. Exp Cell Res. 363:48–64. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu
P, Chen KK, Lopez JP, Poon RT and Fan ST: Octamer 4 (Oct4) mediates
chemotherapeutic drug resistance in liver cancer cells through a
potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology.
52:528–539. 2010.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ,
Gimotty PA, Guerra M, Guo W and Xu X: Acquired cancer stem cell
phenotypes through Oct4-mediated dedifferentiation. Oncogene.
31:4898–4911. 2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Chai S, Ng KY, Tong M, Lau EY, Lee TK,
Chan KW, Yuan YF, Cheung TT, Cheung ST, Wang XQ, et al: Octamer
4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in
liver cancer stem cells. Hepatology. 64:2062–2076. 2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Singh RK, Dhadve A, Sakpal A, De A and Ray
P: An active IGF-1R-AKT signaling imparts functional heterogeneity
in ovarian CSC population. Sci Rep. 6(36612)2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Chen Z, Wang T, Cai L, Su C, Zhong B, Lei
Y and Xiang AP: Clinicopathological significance of non-small cell
lung cancer with high prevalence of Oct-4 tumor cells. J Exp Clin
Cancer Res. 31(10)2012.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Gaafar A, Hamza FN, Yousif R, Shinwari Z,
Alotaibi AG, Iqniebi A, Al-Hussein K, Al-Mazrou A, Manogaran PS,
Elhassan T, et al: Distinct phenotypic and molecular
characteristics of CD34- and CD34+ hematopoietic stem/progenitor
cell subsets in cord blood and bone marrow samples: Implications
for clinical applications. Diagnostics (Basel).
15(447)2025.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Zhao J, Wang Y, Zhou M, Gao J and Yuan Y:
The prognostic effect on childhood acute lymphoblastic leukemia of
CD34(+)CD38(-) expressed in leukemia cells. Hematology. 27:706–713.
2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wang G, Zhou H, Gu Z, Gao Q and Shen G:
Oct4 promotes cancer cell proliferation and migration and leads to
poor prognosis associated with the survivin/STAT3 pathway in
hepatocellular carcinoma. Oncol Rep. 40:979–987. 2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Cioffi M, D'Alterio C, Camerlingo R,
Tirino V, Consales C, Riccio A, Ieranò C, Cecere SC, Losito NS,
Greggi S, et al: Identification of a distinct population of
CD133(+)CXCR4(+) cancer stem cells in ovarian cancer. Sci Rep.
5(10357)2015.PubMed/NCBI View Article : Google Scholar
|
